Intercell Reaches Commercial Stage In US: Japanese Encephalitis Vaccine Gets FDA Okay
This article was originally published in The Pink Sheet Daily
Executive Summary
First vaccine approval for Intercell in US brings a new player fully into the vaccine business; Austrian company has key partnerships pending with Merck, Novartis and Sanofi.
You may also be interested in...
Intercell's Pipeline Setbacks Force Strategic Rethink, Highlight Downside of Option-Based Deals
Two high-profile pipeline setbacks over the past six months have prompted a wholesale strategic rethink at Austria's Intercell AG, one of the few remaining publicly quoted vaccine companies in Europe.
Intercell's Pipeline Setbacks Force Strategic Rethink, Highlight Downside of Option-Based Deals
Two high-profile pipeline setbacks over the past six months have prompted a wholesale strategic rethink at Austria's Intercell AG, one of the few remaining publicly quoted vaccine companies in Europe.
Growing Up: Vaccine Market Increasingly Targets Adults
This past spring, the executive team at 1Intercell AG received the proverbial shot in the arm. After a decade of research and testing, their Ixiaro vaccine for combating Japanese encephalitis was approved by the FDA and then recommended by the Advisory Committee on Immunization Practices